SMARCA4缺陷型胸段肉瘤样肿瘤一线治疗的阳性结果
Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor.
作者信息
Tanaka Shigeru, Hayashi Shuhei, Isobe Yoshitaka, Maruyama Eiichi, Ozawa Hiroaki, Okuno Motoyasu, Kondo Masaru
机构信息
Department of Clinical Laboratory, Okazaki City Hospital, 3-1 Goshoai, Koryuji-cho, Okazaki, 444-8553 Japan.
Department of General Medicine, Okazaki City Hospital, 3-1 Goshoai, Koryuji-cho, Okazaki, 444-8553 Japan.
出版信息
Int Cancer Conf J. 2021 Feb 18;10(2):112-115. doi: 10.1007/s13691-021-00472-4. eCollection 2021 Apr.
Abstract
SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.
摘要
SMARCA4缺陷型胸段肉瘤样肿瘤是一种罕见的恶性肿瘤，具有一些与吸烟相关疾病的特征。本报告的目的是描述一例免疫化学检测显示SMARCA4表达缺失的侵袭性胸段肿瘤病例，并详细介绍我们的治疗方案结果。该患者为一名58岁男性，经临床病理诊断为SMARCA4缺陷型胸段肉瘤样肿瘤。帕博利珠单抗联合卡铂和培美曲塞产生了显著疗效。这种联合治疗显示出对SMARCA4缺陷型胸段肉瘤样肿瘤进行一线全身治疗的潜力。
相似文献
1
Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor.SMARCA4缺陷型胸段肉瘤样肿瘤一线治疗的阳性结果
Int Cancer Conf J. 2021 Feb 18;10(2):112-115. doi: 10.1007/s13691-021-00472-4. eCollection 2021 Apr.
2
A case of radio-insensitive SMARCA4-deficient thoracic undifferentiated carcinoma with severe right heart failure.一例对放疗不敏感的SMARCA4缺陷型胸段未分化癌伴严重右心衰竭。
Respir Med Case Rep. 2021 Feb 18;32:101364. doi: 10.1016/j.rmcr.2021.101364. eCollection 2021.
3
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.41岁SMARCA4缺陷型胸壁肉瘤患者使用伊匹单抗和帕博利珠单抗的混合反应：一项跨学科病例研究
Case Rep Oncol. 2021 May 10;14(2):706-715. doi: 10.1159/000515416. eCollection 2021 May-Aug.
4
A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis.SMARCA4缺陷型胸壁肉瘤病例报告：一种罕见且侵袭性强、预后不良的疾病
Cureus. 2023 May 27;15(5):e39571. doi: 10.7759/cureus.39571. eCollection 2023 May.
5
Thoracic SMARCA4-deficient undifferentiated tumor with associated granulomatous reaction and response to pembrolizumab.伴有相关肉芽肿反应及对帕博利珠单抗有反应的胸段SMARCA4缺陷型未分化肿瘤
Diagn Cytopathol. 2023 Oct;51(10):E287-E293. doi: 10.1002/dc.25190. Epub 2023 Jun 23.
6
Effectiveness of tislelizumab when combined with etoposide and carboplatin in patients with SMARCA4-deficient undifferentiated thoracic tumor: a case report.替雷利珠单抗联合依托泊苷和顺铂治疗SMARCA4缺陷型未分化胸腺瘤患者的疗效：一例报告
Transl Cancer Res. 2023 Apr 28;12(4):1041-1048. doi: 10.21037/tcr-22-1679. Epub 2023 Mar 16.
7
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.对 PD-L1 过表达的 SMARCA4 缺陷型胸肉瘤患者使用派姆单抗的快速反应：病例报告。
Thorac Cancer. 2019 Dec;10(12):2312-2315. doi: 10.1111/1759-7714.13215. Epub 2019 Oct 16.
8
SMARCA4-deficient rectal carcinoma with a sarcomatoid component: a case report.SMARCA4 缺陷型伴有肉瘤样成分的直肠腺癌：病例报告。
Clin J Gastroenterol. 2022 Apr;15(2):419-426. doi: 10.1007/s12328-022-01602-y. Epub 2022 Feb 7.
9
Small Intestine Metastasis Leads to the Diagnosis of Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report.小肠转移瘤导致胸段SMARCA4缺陷型未分化肿瘤的诊断：一例报告
Cureus. 2024 Sep 1;16(9):e68364. doi: 10.7759/cureus.68364. eCollection 2024 Sep.
10
Chemotherapy and Immune Checkpoint Inhibitors in a Case of SMARCA4-dUT: A Case Report and Review of Literature.SMARCA4-dUT 病例中的化疗和免疫检查点抑制剂：病例报告及文献复习。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231176220. doi: 10.1177/23247096231176220.
引用本文的文献
1
Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features.帕博利珠单抗与安罗替尼联合治疗胸段SMARCA4缺陷型未分化肿瘤的长期随访：1例病例报告及分子特征
Front Oncol. 2024 Dec 11;14:1453895. doi: 10.3389/fonc.2024.1453895. eCollection 2024.
2
Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4-UT Without PD-L1 Expression: A Case Report and Review of Literature.培米普利单抗联合安罗替尼及化疗对无PD-L1表达的胸段SMARCA4-UT的快速反应：一例报告及文献复习
Clin Respir J. 2024 Dec;18(12):e70036. doi: 10.1111/crj.70036.
3
Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor.胸段SMARCA4缺陷型肿瘤：52例SMARCA4缺陷型非小细胞肺癌及20例胸段SMARCA4缺陷型未分化肿瘤的临床病理分析
PeerJ. 2024 Feb 16;12:e16923. doi: 10.7717/peerj.16923. eCollection 2024.
4
The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation.打开 SMARCA4 缺陷未分化胸腺瘤神秘盒子的金钥匙：聚焦免疫治疗、肿瘤微环境和表观遗传调控。
Cancer Gene Ther. 2024 May;31(5):687-697. doi: 10.1038/s41417-024-00732-4. Epub 2024 Feb 13.
5
Chemotherapy and Immune Checkpoint Inhibitors in a Case of SMARCA4-dUT: A Case Report and Review of Literature.SMARCA4-dUT 病例中的化疗和免疫检查点抑制剂：病例报告及文献复习。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231176220. doi: 10.1177/23247096231176220.
6
A case of thoracic -Deficient undifferentiated tumor successfully treated with combination Ipilimumab-Nivolumab.一例胸段未分化肿瘤经伊匹单抗-纳武单抗联合治疗成功治愈。
Clin Case Rep. 2022 Dec 13;10(12):e6745. doi: 10.1002/ccr3.6745. eCollection 2022 Dec.
7
Rare tumor subtypes diagnosed by molecular analysis.通过分子分析诊断出的罕见肿瘤亚型。
Int Cancer Conf J. 2021 Mar 8;10(2):95. doi: 10.1007/s13691-021-00476-0. eCollection 2021 Apr.
本文引用的文献
1
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.免疫检查点抑制剂在SMARCA4突变型非小细胞肺癌中的疗效
J Thorac Oncol. 2020 Aug;15(8):e133-e136. doi: 10.1016/j.jtho.2020.03.030.
2
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.SMARCA4 缺陷性胸肉瘤治疗中纳武利尤单抗显著应答：病例报告
Immunotherapy. 2020 Jun;12(8):563-569. doi: 10.2217/imt-2019-0142. Epub 2020 May 3.
3
Clinicopathologic Characteristics of BRG1-Deficient NSCLC.BRG1缺陷型非小细胞肺癌的临床病理特征
J Thorac Oncol. 2020 May;15(5):766-776. doi: 10.1016/j.jtho.2020.01.002. Epub 2020 Jan 24.
4
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.SMARCA4 缺陷型胸肉瘤样肿瘤主要为与吸烟相关的未分化癌，而非原发性胸肉瘤。
J Thorac Oncol. 2020 Feb;15(2):231-247. doi: 10.1016/j.jtho.2019.10.023. Epub 2019 Nov 18.
5
Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.帕博利珠单抗对胸腔恶性横纹肌样样SMARCA4缺陷型肿瘤产生持久的主要反应。
Ann Oncol. 2019 Aug 1;30(8):1401-1403. doi: 10.1093/annonc/mdz160.
6
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.SMARCA4 失活定义了一组未分化的胸恶性肿瘤，这些肿瘤在转录上与 BAF 缺陷型肉瘤相关。
Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.
7
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
8
Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.胚系和体细胞 SMARCA4 突变特征性表现为卵巢，高钙血症型小细胞癌。
Nat Genet. 2014 May;46(5):438-43. doi: 10.1038/ng.2931. Epub 2014 Mar 23.
9
SWI/SNF nucleosome remodellers and cancer.SWI/SNF 核小体重塑因子与癌症。
Nat Rev Cancer. 2011 Jun 9;11(7):481-92. doi: 10.1038/nrc3068.
10
Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.胚系无义突变和体细胞失活的 SMARCA4/BRG1 在一个具有横纹肌瘤易感性综合征的家族中。
Am J Hum Genet. 2010 Feb 12;86(2):279-84. doi: 10.1016/j.ajhg.2010.01.013. Epub 2010 Feb 4.
Zotero 插件